Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsNA

The Effect of Ketone Monoesters on Skeletal Muscle Protein Synthesis and Whole-body Protein Metabolism.

Sponsor: University of Exeter

NCT ID: NCT07082309

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Access to the study treatment being tested
Type of study
Interventional (receives a drug or procedure)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Ketone Monoester (KE) and whey protein beverage (supplement), Control (supplement)
How long the study runs
Study runs about 25 months (dates as stated)
About the drug or intervention
Ketone Monoester (KE) and whey protein beverage — supplement: Ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate) and whey protein (0.3 g/kg) · Control — supplement: Placebo with bitter agent (Bitrex), to flavour match to ketone condition, whey protein (0.3 g/kg), and milk fat (to match the caloric content of the ketone condition).
Patient visit burden
Not specified by the sponsor
Type of study
Testing a treatment
Ages
18 Years to 40 Years
Who
All
Number of participants
12
Started
2025-06-04
Last checked
2025-07

Plain English Summary

What is this study?

  • • Testing a new treatment for healthy participants
  • • NA - 12 participants
  • • The ketone β-hydroxybutyrate (BHB) is endogenously produced during periods of low glucose availability, serving as an alternative metabolic fuel

Who can take part?

  • • Ages 18 Years to 40 Years
  • • Diagnosed with healthy participants

Where?

  • • Exeter - Health and Life Sciences

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The ketone β-hydroxybutyrate (BHB) is endogenously produced during periods of low glucose availability, serving as an alternative metabolic fuel. Beyond its role as an energy substrate, BHB acts as a pleiotropic signalling molecule, modulating various physiological processes across multiple tissues. BHB can also be ingested orally as a ketone monoester, transiently elevating plasma concentrations of BHB to a level similar to those seen following several days of fasting, thereby obviating the need for dietary manipulation. The influence of BHB on human skeletal muscle protein metabolism remains poorly understood, although emerging evidence suggests that BHB may play a role in regulating muscle protein turnover. As such, BHB supplementation may support skeletal muscle remodelling and offer therapeutic benefits, and investigating this is of considerable interest. This study will investigate the ability of oral BHB ingestion - co-ingested with protein - to stimulate skeletal muscle anabolism in young healthy adults. A dual amino acid stable isotope tracer approach will be utilised to determine postprandial (i.e., fed state) muscle protein synthesis (MPS) rates and whole-body amino acid kinetics, given BHBs systemic effects. This research will advance our understanding of the fundamental biology of exogenous ketosis and provide insight into the potential of BHB supplementation as a novel nutritional strategy to optimise muscle mass and quality.

More detail

The ketone body β-hydroxybutyrate (BHB) is produced endogenously during periods of low glucose availability (e.g., fasting or starvation) and provides an alternative metabolic fuel. BHB also acts as a metabolic signalling molecule, modulating physiological processes across multiple tissues, including skeletal muscle. However, the impact of exogenous ketosis on muscle protein turnover, which regulates muscle mass and modulates physical function, remains largely unexplored. As such, understanding how BHB affects skeletal muscle protein turnover is fundamentally important. The ingestion of 0.5g/kg body mass BHB appreciably increases plasma BHB concentrations for several hours, to \~3-5 mM; equivalent to several days of fasting. This offers a model to exogenously elevate plasma BHB concentrations and investigate how BHB interacts with feeding to affect postprandial protein metabolism, the period primarily responsible for driving changes in muscle quality and quantity. An early study demonstrated that the infusion of BHB stimulates muscle protein synthesis rates (MPS), whilst only a single recent study has investigated the effect of oral BHB ingestion (exogenous ketosis) on MPS. Prior work demonstrated that the ingestion of an oral ketone monoester stimulated MPS, and it did so to a similar extent as 10 g whey protein or co-ingestion of the two, in healthy young males. While this study provides useful insights, several unanswered questions/objectives that justify the need for further investigation remain: * To determine how BHB ingestion influences myofibrillar protein synthesis, plasma amino acid concentrations, and amino acid kinetics following the co-ingestion of a physiologically relevant meal-like protein dose. * To examine how BHB ingestion affects plasma amino acid concentrations and kinetics following protein co-ingestion, addressing prior research limitations where differences in carbohydrate intake and postprandial insulin levels confounded the independent effects of ketones. * To assess the impact of BHB ingestion on whole-body protein metabolism following protein co-ingestion, as previous studies have not examined its potential influence on protein breakdown, amino acid kinetics, and net protein balance. * To investigate whether BHB ingestion influences mitochondrial muscle protein synthesis following protein co-ingestion, given its established effects on mitochondrial metabolism, yet unexamined role in mitochondrial protein turnover. The aim, therefore, is to establish the effect of BHB and protein co-ingestion on myofibrillar protein synthesis rates, mitochondrial protein synthesis rates, and whole-body protein turnover. We will address this question by utilising a meal-like bolus of protein (0.3 g/kg whey protein), with and without 0.5g/kg body mass BHB (matching the test drinks caloric content via the addition of fat to minimally stimulate insulin secretion), whilst applying a dual-stable isotope tracer approach.

Healthy Participants

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years - 40 Years
  • Who can join: All genders

What the study is looking for

  • ✓BMI 18-30

Who cannot take part

  • ✗Body mass index (BMI) \< 18.5 or \> 30 kg/m2
  • ✗Age \< 18 or \> 40
  • ✗Regularly smokes
  • ✗Type 2 diabetes
  • ✗Cardiovascular disease, metabolic disease and hypertension (≥ 140/90 mmHg)
See the full criteria
Inclusion Criteria: • BMI 18-30 Exclusion Criteria: * Body mass index (BMI) \< 18.5 or \> 30 kg/m2 * Age \< 18 or \> 40 * Regularly smokes * Type 2 diabetes * Cardiovascular disease, metabolic disease and hypertension (≥ 140/90 mmHg) * Gastrointestinal disorders * Use medicines that may impact protein metabolism or that are anti-inflammatory (determined at the screening) * Pregnancy

Where Is This Study? (1 UK site)

Health and Life Sciences

Exeter EX1 2LU, United Kingdom

Recruiting
Site contact (verified)
Alistair Monteyne, PhDPrincipal Investigator

How to Get in Touch

Alistair Monteyne, PhD

Sponsor contact

CONTACT

+44 (0)1392 72 4774 a.monteyne2@exeter.ac.uk
Data sourced from ClinicalTrials.gov · Last verified: 2025-07